Despite the additive effect observed with the combination of PIVKA‐II to AFP in BCLC‐C HCC patients (AUROC 95.7%), this could not be of major importance as each biomarker separately produces quite high results in the HCC diagnosis of advance stage patients (AUROC 94.3% for AFP and 91.3% for PIVKA‐II). This evidence concerns the gene AFP and hepatocellular carcinoma.